BRPI0519317A2 - mÉtodo para marcar um vetor, composto, composiÇço radiofarmacÊutica, uso de um composto, e, mÉtodos para gerar uma imagem de um corpo humano ou animal e para monitorar o efeito do tratamento de um corpo humano ou animal com uma droga para combater uma condiÇço associada com cÂncer - Google Patents

mÉtodo para marcar um vetor, composto, composiÇço radiofarmacÊutica, uso de um composto, e, mÉtodos para gerar uma imagem de um corpo humano ou animal e para monitorar o efeito do tratamento de um corpo humano ou animal com uma droga para combater uma condiÇço associada com cÂncer

Info

Publication number
BRPI0519317A2
BRPI0519317A2 BRPI0519317-6A BRPI0519317A BRPI0519317A2 BR PI0519317 A2 BRPI0519317 A2 BR PI0519317A2 BR PI0519317 A BRPI0519317 A BR PI0519317A BR PI0519317 A2 BRPI0519317 A2 BR PI0519317A2
Authority
BR
Brazil
Prior art keywords
compound
human
animal body
methods
formula
Prior art date
Application number
BRPI0519317-6A
Other languages
English (en)
Portuguese (pt)
Inventor
Erik Arstad
Matthias Eberhard Glaser
Original Assignee
Hammersmith Imanet Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hammersmith Imanet Ltd filed Critical Hammersmith Imanet Ltd
Publication of BRPI0519317A2 publication Critical patent/BRPI0519317A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/082—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being a RGD-containing peptide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/1051—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from breast, e.g. the antibody being herceptin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
BRPI0519317-6A 2004-12-22 2005-12-09 mÉtodo para marcar um vetor, composto, composiÇço radiofarmacÊutica, uso de um composto, e, mÉtodos para gerar uma imagem de um corpo humano ou animal e para monitorar o efeito do tratamento de um corpo humano ou animal com uma droga para combater uma condiÇço associada com cÂncer BRPI0519317A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0428012.9A GB0428012D0 (en) 2004-12-22 2004-12-22 Radiolabelling methods
PCT/GB2005/004729 WO2006067376A2 (en) 2004-12-22 2005-12-09 Radiolabelled conjugates of rgd-containing peptides and methods for their preparation via click-chemistry

Publications (1)

Publication Number Publication Date
BRPI0519317A2 true BRPI0519317A2 (pt) 2009-01-13

Family

ID=34112991

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0519317-6A BRPI0519317A2 (pt) 2004-12-22 2005-12-09 mÉtodo para marcar um vetor, composto, composiÇço radiofarmacÊutica, uso de um composto, e, mÉtodos para gerar uma imagem de um corpo humano ou animal e para monitorar o efeito do tratamento de um corpo humano ou animal com uma droga para combater uma condiÇço associada com cÂncer

Country Status (13)

Country Link
US (2) US7972588B2 (https=)
EP (4) EP1830890A2 (https=)
JP (2) JP5743372B2 (https=)
KR (1) KR101314460B1 (https=)
CN (2) CN105012972A (https=)
AU (1) AU2005317903C1 (https=)
BR (1) BRPI0519317A2 (https=)
CA (2) CA2817636A1 (https=)
GB (1) GB0428012D0 (https=)
MX (1) MX2007007560A (https=)
NO (1) NO341638B1 (https=)
RU (1) RU2419627C2 (https=)
WO (1) WO2006067376A2 (https=)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8071718B2 (en) 2004-12-22 2011-12-06 General Electric Company Selective radiolabeling of biomolecules
GB0428012D0 (en) * 2004-12-22 2005-01-26 Hammersmith Imanet Ltd Radiolabelling methods
WO2007148074A1 (en) * 2006-06-21 2007-12-27 Hammersmith Imanet Limited Chemical methods and apparatus
JP2009541288A (ja) 2006-06-21 2009-11-26 ハマースミス・イメイネット・リミテッド 放射性標識方法
EP2056886A2 (en) * 2006-08-28 2009-05-13 GE Healthcare Limited 68ga-labeled peptide-based radiopharmaceuticals
WO2008025886A1 (en) * 2006-09-01 2008-03-06 Wallac Oy Metal chelates and chelating agents containing triazolyl subunits
EP2155259A2 (en) * 2007-05-10 2010-02-24 The Trustees of Columbia University in the City of New York Methods for diagnosing diseases and evaluating treatments therefor using pet
KR101563758B1 (ko) * 2007-12-20 2015-10-27 제너럴 일렉트릭 캄파니 생체분자의 선택적 방사선표지
EP2147684A1 (en) * 2008-07-22 2010-01-27 Bracco Imaging S.p.A Diagnostic Agents Selective Against Metalloproteases
GB0815831D0 (en) * 2008-09-01 2008-10-08 Imp Innovations Ltd Compounds
KR20110066927A (ko) 2008-09-05 2011-06-17 임페리얼 이노베이션스 리미티드 생체 내 영상화제로서 사용하기 위한 이사틴 유도체
CA2736861C (en) * 2008-10-10 2017-11-14 Roger Schibli 18f-labelled folates as pet radiotracers
US20120165650A1 (en) 2010-12-22 2012-06-28 General Electric Company Her2 binders
EP2210882A1 (en) * 2009-01-16 2010-07-28 Commissariat à l'Énergie Atomique et aux Énergies Alternatives Synthesis of new protected azahistidine, their processes and their use in synthesises
EP2400992B1 (en) * 2009-02-27 2015-07-22 Genentech, Inc. Methods and compositions for protein labelling
US8722014B2 (en) * 2009-05-01 2014-05-13 Washington University 1 H-[1, 2, 3] triazole substituted amino acids and uses thereof
GB0914543D0 (en) * 2009-08-20 2009-09-30 Ge Healthcare Ltd Radioiodination method
WO2011058002A1 (en) * 2009-11-11 2011-05-19 Neurosearch A/S Labelled pyrrolyl-oxadiazolyl-diazabicyclononane derivatives and their use in diagnostic methods
GB0921573D0 (en) * 2009-12-10 2010-01-27 Ge Healthcare Ltd Iodine radiolabelling method
GB0922304D0 (en) 2009-12-22 2010-02-03 Ge Healthcare Ltd Radioiodinated compounds
WO2011079245A1 (en) * 2009-12-23 2011-06-30 Board Of Regents Of The University Of Nebraska Targeted radiolabeled compounds and their use for the treatment and diagnosis of cancer
WO2011130530A1 (en) * 2010-04-14 2011-10-20 The Mclean Hospital Corporation 2-alkoxy-11-hydroxyaporphine derivatives and uses thereof
WO2011153250A2 (en) 2010-06-01 2011-12-08 Advanced Proteome Therapeutics Inc. Crosslinking of proteins and other entities via conjugates of alpha-haloacetophenones, benzyl halides, quinones, and their derivatives
US10434197B2 (en) * 2010-07-23 2019-10-08 University Of Delaware Tetrazine-trans-cyclooctene ligation for the rapid construction of radionuclide labeled probes
GB201014023D0 (en) * 2010-08-20 2010-10-06 Ucl Business Plc Process for producing bioconjugates and products thereof
WO2012074840A2 (en) 2010-11-22 2012-06-07 The General Hospital Corporation Compositions and methods for in vivo imaging
GB201019824D0 (en) 2010-11-23 2011-01-05 Ge Healthcare Ltd Radioiodination method
GB201021369D0 (en) 2010-12-16 2011-01-26 Ge Healthcare Ltd Radioiodinated fatty acids
GB201021517D0 (en) 2010-12-20 2011-02-02 Ge Healthcare Ltd Radioiodinated guanidines
RU2013128360A (ru) 2010-12-22 2015-01-27 ДжиИ ХЕЛТКЕР ЛИМИТЕД Her2-связывающие белки, меченые 18f-содержащим кремнийорганическим соединением
NZ612161A (en) 2010-12-22 2015-04-24 Gen Electric Radiolabled her2 binding peptides
AU2012223364A1 (en) 2011-03-01 2013-09-19 Ge Healthcare Limited Radiolabelled Octreotate analogues as PET tracers
US20120251448A1 (en) * 2011-03-03 2012-10-04 Hefti Franz F Compounds for Use in the Detection of Neurodegenerative Diseases
US9023318B2 (en) * 2011-06-08 2015-05-05 Siemens Medical Solutions Usa, Inc. Compounds with matrix-metalloproteinase inhibitory activity and imaging agents thereof
WO2013048832A1 (en) 2011-09-29 2013-04-04 Ge Healthcare Limited 18 f - labelled 6 - ( 2 - fluoroethoxy) - 2 - naphthaldehyde for detecting cancer stem cells
WO2013048811A1 (en) 2011-09-30 2013-04-04 Ge Healthcare Limited Imaging and radiotherapy methods for tumour stem cells
WO2013082508A1 (en) * 2011-12-02 2013-06-06 The Regents Of The University Of Michigan Compositions and methods for the treatment and analysis of neurological disorders
GB201121911D0 (en) 2011-12-20 2012-02-01 Ge Healthcare Ltd Radiofluorination method
WO2013113680A1 (en) * 2012-02-03 2013-08-08 Aarhus Universitet Radiolabeled bile acids and bile acid derivatives
EP2657213A1 (en) * 2012-04-24 2013-10-30 Institut National de la Santé et de la Recherche Medicale Labelled quinoxaline derivatives as multimodal radiopharmaceuticals and their precursors
US20140065070A1 (en) * 2012-08-28 2014-03-06 Mcmaster University Methods of preparing triazole-containing radioiodinated compounds
WO2014065413A1 (ja) * 2012-10-26 2014-05-01 日本たばこ産業株式会社 トリアゾール・イソオキサゾール化合物およびその医薬用途
US20150023877A1 (en) * 2013-07-18 2015-01-22 The Board Of Trustees Of The Leland Stanford Junior University Methods of parkinsons disease diagnosis and monitoring treatment
CA2935857C (en) * 2014-01-05 2020-12-15 Washington University Radiolabeled tracers for poly (adp-ribose) polymerase-1 (parp-1), methods and uses therefor
US20160022846A1 (en) * 2014-07-22 2016-01-28 Ge Healthcare Limited Iodine radiolabelling method
SMT202000633T1 (it) * 2015-06-19 2021-01-05 Eisai R&D Man Co Ltd Immunoglobuline coniugate a cys80
US10434195B2 (en) * 2015-08-03 2019-10-08 Emory University Methylsulfonamide derivatives and uses related thereto
WO2019227490A1 (en) 2018-06-01 2019-12-05 Tayu Huaxia Biotech Medical Group Co., Ltd. Compositions and methods for imaging
EP3826673A4 (en) * 2018-07-26 2022-03-09 Tayu Huaxia Biotech Medical Group Co., Ltd. COMPOSITIONS AND METHODS FOR IMAGING

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4913891A (en) * 1986-04-17 1990-04-03 The United States Of America As Represented By The United States Department Of Energy Positron emitter labeled enzyme inhibitors
AU4589701A (en) 2000-03-24 2001-10-08 Cocensys Inc Aryl substituted pyrazoles, triazoles and tetrazoles, and the use thereof
US6350360B1 (en) 2000-04-07 2002-02-26 Sandia Coroporation Method of fabricating a 3-dimensional tool master
CA2405469C (en) * 2000-04-12 2012-03-20 Amersham Health As Integrin binding peptide derivatives
GB0115927D0 (en) 2001-06-29 2001-08-22 Nycomed Amersham Plc Solid-phase nucleophilic fluorination
BRPI0210886B8 (pt) 2001-07-10 2021-05-25 Amersham Health As composto, composição farmacêutica, uso de um composto, e, métodos de geração de imagens, de monitoração do efeito do tratamento de um corpo humano ou animal com uma droga para combater uma condição associada com câncer e de tratamento de câncer ou de uma doença relacionada em um corpo humano ou animal
JP4638225B2 (ja) 2002-05-30 2011-02-23 ザ スクリプス リサーチ インスティテュート 銅を触媒とするアジドとアセチレンのライゲーション
WO2004055160A2 (en) * 2002-12-13 2004-07-01 The Trustees Of Columbia University In The City Of New York Biomolecular coupling methods using 1,3-dipolar cycloaddition chemistry
JP5642916B2 (ja) * 2003-04-17 2014-12-17 ザ スクリプス リサーチ インスティテュート 真核遺伝コードの拡張
EP2410331B1 (en) * 2003-06-18 2015-09-23 The Scripps Research Institute Aminoacyl-tRNA synthetase for aminoacylation tRNA with unnatural amino acids
NO20033115D0 (no) 2003-07-08 2003-07-08 Amersham Health As Peptid-baserte forbindelser
EP1809339A2 (en) * 2004-10-07 2007-07-25 Koninklijke Philips Electronics N.V. Compounds, kits and methods for use in medical imaging
GB0428012D0 (en) * 2004-12-22 2005-01-26 Hammersmith Imanet Ltd Radiolabelling methods

Also Published As

Publication number Publication date
KR101314460B1 (ko) 2013-10-10
GB0428012D0 (en) 2005-01-26
US8679455B2 (en) 2014-03-25
AU2005317903C1 (en) 2012-05-10
JP2012254998A (ja) 2012-12-27
JP2008528445A (ja) 2008-07-31
US20110236311A1 (en) 2011-09-29
NO20073157L (no) 2007-06-20
CA2589136C (en) 2015-10-06
CN101084020A (zh) 2007-12-05
RU2007122804A (ru) 2009-01-27
CA2589136A1 (en) 2006-06-29
AU2005317903A1 (en) 2006-06-29
CN105012972A (zh) 2015-11-04
MX2007007560A (es) 2007-11-21
EP2266629B1 (en) 2015-12-09
AU2005317903B2 (en) 2011-12-01
EP2266629A1 (en) 2010-12-29
CA2817636A1 (en) 2006-06-29
RU2419627C2 (ru) 2011-05-27
EP2258403A1 (en) 2010-12-08
EP2275145A1 (en) 2011-01-19
JP5743372B2 (ja) 2015-07-01
WO2006067376A3 (en) 2007-07-26
WO2006067376A2 (en) 2006-06-29
US20090311177A1 (en) 2009-12-17
US7972588B2 (en) 2011-07-05
KR20070091626A (ko) 2007-09-11
AU2005317903B8 (en) 2012-01-19
EP1830890A2 (en) 2007-09-12
NO341638B1 (no) 2017-12-18

Similar Documents

Publication Publication Date Title
BRPI0519317A2 (pt) mÉtodo para marcar um vetor, composto, composiÇço radiofarmacÊutica, uso de um composto, e, mÉtodos para gerar uma imagem de um corpo humano ou animal e para monitorar o efeito do tratamento de um corpo humano ou animal com uma droga para combater uma condiÇço associada com cÂncer
WO2007148089A3 (en) Radiolabelling methods
Müller et al. Terbium-161 for PSMA-targeted radionuclide therapy of prostate cancer
WO2015073746A3 (en) 18f labeling of proteins using sortases
bin Othman et al. Re-assessing gallium-67 as a therapeutic radionuclide
MX2009002775A (es) Derivados de ciclopeptido de quimica click como agentes de formacion de imagen para integrinas.
PH12013500270A1 (en) Peptide radiotracer compositions
Obata et al. Intra-tumoral distribution of 64Cu-ATSM: a comparison study with FDG
ATE411819T1 (de) Konjugate für medizinische abbildungen umfassend träger, targeting-anteile und kontrastmittel
Maleki et al. Structural modifications of amino acid sequences of radiolabeled peptides for targeted tumor imaging
Boschi et al. 188Re (V) nitrido radiopharmaceuticals for radionuclide therapy
WO2009134405A3 (en) Substrate based pet imaging agents
Métivier et al. Preclinical evaluation of a 64Cu-based theranostic approach in a murine model of multiple myeloma
Kauffman et al. Intra-arterial delivery of radiopharmaceuticals in oncology: current trends and the future of alpha-particle therapeutics
Liu et al. Experimental therapy of HER2-expressing xenografts using the second-generation HER2-targeting Affibody molecule 188Re-ZHER2: 41071
BRPI0409101A (pt) método para produzir um complexo de gálio radiomarcado
WO2009018175A3 (en) Cyclic azapeptides as integrin markers
WO2009134382A3 (en) Cyclopeptides containing rgd mimetics as imaging markers for integrins
Kondo et al. Radioiodinated bicyclic RGD peptide derivatives for enhanced tumor accumulation
Miao et al. Therapeutic efficacy of a 177Lu-labeled DOTA conjugated α-melanocyte-stimulating hormone peptide in a murine melanoma-bearing mouse model
Kanellopoulos et al. Key-protease inhibition regimens promote tumor targeting of neurotensin radioligands
Maisonial et al. Synthesis, radioiodination and in vivo screening of novel potent iodinated and fluorinated radiotracers as melanoma imaging and therapeutic probes
BRPI0518636A2 (pt) kits nço-radioativo liofilizado e de multi-doses, processo para a preparaÇço de méltiplas doses de paciente unitÁrias do radiofarmacÊutico tetrofosmina-99mtc, composiÇço radiofarmacÊutica estabilizada, e, dose de paciente unitÁria do radiofarmacÊutico tetrofosmina-99mtc
RAMLI et al. Preclinical study of 177Lu-DOTA-trastuzumab: A potential radiopharmaceutical for therapy of breast cancer positive HER-2
Szücs et al. Investigation of the effect on the albumin binding moiety for the pharmacokinetic properties of 68ga-, 205/206bi-, and 177Lu-Labeled NAPamide-Based radiopharmaceuticals

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]

Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO POR NAO SE ENQUADRAR NO ART. 229-C DA LPI.

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 8O C/C 11, 8O C/C 13 E 25 DA LPI.

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.